KBC Group NV Trims Stock Position in LivaNova PLC (NASDAQ:LIVN)

KBC Group NV trimmed its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 56.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,487 shares of the company's stock after selling 56,441 shares during the period. KBC Group NV owned approximately 0.08% of LivaNova worth $1,708,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of LIVN. UMB Bank n.a. boosted its stake in LivaNova by 340.5% in the first quarter. UMB Bank n.a. now owns 837 shares of the company's stock valued at $33,000 after acquiring an additional 647 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after buying an additional 219 shares during the period. Sterling Capital Management LLC lifted its stake in shares of LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after buying an additional 1,441 shares during the period. Central Pacific Bank Trust Division lifted its stake in shares of LivaNova by 7.0% during the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock worth $173,000 after buying an additional 290 shares during the period. Finally, Vestcor Inc acquired a new stake in shares of LivaNova during the fourth quarter worth $204,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Stock Performance

Shares of LivaNova stock traded up $0.05 during trading on Friday, hitting $46.13. 243,250 shares of the company's stock were exchanged, compared to its average volume of 638,315. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.37 and a current ratio of 1.58. The business has a 50-day simple moving average of $43.64 and a 200-day simple moving average of $43.31. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $57.35. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of -11.28 and a beta of 0.90.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LIVN. Needham & Company LLC reiterated a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research note on Tuesday, May 13th. Wall Street Zen downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a research note on Tuesday, May 20th. Barclays lowered their price objective on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research note on Thursday, May 8th. Finally, Robert W. Baird lifted their price objective on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.